TY  - GEN
AU  - Greenspan,Susan L
AU  - Emkey,Ronald D
AU  - Bone,Henry G
AU  - Weiss,Stuart R
AU  - Bell,Norman H
AU  - Downs,Robert W
AU  - McKeever,Clark
AU  - Miller,Sam S
AU  - Davidson,Michael
AU  - Bolognese,Michael A
AU  - Mulloy,Anthony L
AU  - Heyden,Norman
AU  - Wu,Mei
AU  - Kaur,Amarjot
AU  - Lombardi,Antonio
TI  - Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial
SN  - 1539-3704
PY  - 2002///1217
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Alendronate
KW  - adverse effects
KW  - Biomarkers
KW  - analysis
KW  - Bone Density
KW  - drug effects
KW  - Double-Blind Method
KW  - Drug Therapy, Combination
KW  - Estrogen Replacement Therapy
KW  - Estrogens, Conjugated (USP)
KW  - Female
KW  - Hip
KW  - physiology
KW  - Humans
KW  - Lumbar Vertebrae
KW  - Middle Aged
KW  - Osteoporosis, Postmenopausal
KW  - drug therapy
KW  - Placebos
KW  - Treatment Outcome
KW  - Withholding Treatment
N1  - Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.7326/0003-4819-137-11-200212030-00008
ER  -